Sobi (STO: SOBI) and Enable Injections, Inc. have announced a global (ex-US) development agreement and supply agreement across Sobi territories for the enFuse Injector, for the subcutaneous delivery of Aspaveli (pegcetacoplan).
Latham & Watkins LLP advised Sobi in the transaction with a corporate deal team led by San Diego partner Steve Chinowsky, London associate Oliver Mobasser, and San Diego counsel Darryl Steensma.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
